Characteristics of 1076 patients who received BTK inhibitors
| Patient and disease characteristics . | N = 1076 (%) . |
|---|---|
| Age, y (median) | 72 (IQR, 64-78) |
| Sex (%) | |
| Male | 777 (72%) |
| Female | 299 (28%) |
| Practice type (%) | |
| Community | 885 (82%) |
| Academic | 191 (17%) |
| Race (%) | |
| White | 830 (77%) |
| Black or African American | 37 (4%) |
| Asian | 7 (1%) |
| Others/not reported | 202 (19%) |
| Stage (%) | |
| Stage I/II | 48 (4%) |
| Stage III/IV | 803 (75%) |
| Unknown | 225 (21%) |
| Disease subtype (%) | |
| Blastoid | 110 (10%) |
| Leukemic | 51 (5%) |
| Pleomorphic | 39 (4%) |
| NOS | 876 (81%) |
| Deletion 17p or TP53 mutation (%) | |
| Present | 76 (8%) |
| Absent | 468 (43%) |
| Unknown/not documented | 532 (49%) |
| ECOG (%) | |
| 0-1 | 500 (46%) |
| 2-4 | 102 (10%) |
| Unknown | 474 (44%) |
| LDH above ULN (%) | |
| No | 429 (39%) |
| Yes | 219 (20%) |
| Unknown | 428(41%) |
| Ki-67 index > 30% | |
| No | 211 (20%) |
| Yes | 436 (40%) |
| Unknown | 429 (40%) |
| Other characteristics of patients receiving BTK inhibitors | |
| Lines of therapy (median) | 2 (IQR, 2-3) |
| Prior autologous stem cell transplant (n) | 114 |
| Time to BTK inhibitor initiation from diagnosis (median) | 19 mo (IQR, 6-38) |
| Type of BTK inhibitor | |
| Ibrutinib | 843 (78%) |
| Acalabrutinib | 211 (20%) |
| Zanubrutinib | 22 (2%) |
| Median follow-up duration by reverse KM method from start of BTK inhibitor | 35 mo (IQR, 15-59) |
| Median time to next treatment by time to event analysis | 13 mo (95% CI, 11-15) |
| rwOS (median) entire cohort | 23 mo (95% CI, 21-27) |
| rwOS (median) for frontline therapy | 35 mo (95% CI, 27-50) |
| rwOS (median) for second-line therapy | 24 mo (95% CI, 22-30) |
| rwOS (median) for third or later line therapy | 18 mo (95% CI, 14-21) |
| Patient and disease characteristics . | N = 1076 (%) . |
|---|---|
| Age, y (median) | 72 (IQR, 64-78) |
| Sex (%) | |
| Male | 777 (72%) |
| Female | 299 (28%) |
| Practice type (%) | |
| Community | 885 (82%) |
| Academic | 191 (17%) |
| Race (%) | |
| White | 830 (77%) |
| Black or African American | 37 (4%) |
| Asian | 7 (1%) |
| Others/not reported | 202 (19%) |
| Stage (%) | |
| Stage I/II | 48 (4%) |
| Stage III/IV | 803 (75%) |
| Unknown | 225 (21%) |
| Disease subtype (%) | |
| Blastoid | 110 (10%) |
| Leukemic | 51 (5%) |
| Pleomorphic | 39 (4%) |
| NOS | 876 (81%) |
| Deletion 17p or TP53 mutation (%) | |
| Present | 76 (8%) |
| Absent | 468 (43%) |
| Unknown/not documented | 532 (49%) |
| ECOG (%) | |
| 0-1 | 500 (46%) |
| 2-4 | 102 (10%) |
| Unknown | 474 (44%) |
| LDH above ULN (%) | |
| No | 429 (39%) |
| Yes | 219 (20%) |
| Unknown | 428(41%) |
| Ki-67 index > 30% | |
| No | 211 (20%) |
| Yes | 436 (40%) |
| Unknown | 429 (40%) |
| Other characteristics of patients receiving BTK inhibitors | |
| Lines of therapy (median) | 2 (IQR, 2-3) |
| Prior autologous stem cell transplant (n) | 114 |
| Time to BTK inhibitor initiation from diagnosis (median) | 19 mo (IQR, 6-38) |
| Type of BTK inhibitor | |
| Ibrutinib | 843 (78%) |
| Acalabrutinib | 211 (20%) |
| Zanubrutinib | 22 (2%) |
| Median follow-up duration by reverse KM method from start of BTK inhibitor | 35 mo (IQR, 15-59) |
| Median time to next treatment by time to event analysis | 13 mo (95% CI, 11-15) |
| rwOS (median) entire cohort | 23 mo (95% CI, 21-27) |
| rwOS (median) for frontline therapy | 35 mo (95% CI, 27-50) |
| rwOS (median) for second-line therapy | 24 mo (95% CI, 22-30) |
| rwOS (median) for third or later line therapy | 18 mo (95% CI, 14-21) |
ULN, upper limit of normal.